ArticleAntimicrobial agents and chemotherapy2006
Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Clinical features and antifungal treatment of invasive Scedosporium boydii infection: report of a case and literature overview.Annals of clinical microbiology and antimicrobials · 2024Review
- An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.Clinical microbiology reviews · 2024Review
- Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.Clinical microbiology reviews · 2024Review
- A new record ofCurrent medical mycology · 2022Article
- Isolated cutaneousJAAD case reports · 2022Article
- Repurposing of auranofin and honokiol as antifungals againstVirulence · 2021Article
- Fatal pulmonaryCurrent medical mycology · 2021Article
- Fungal Genomics in Respiratory Medicine: What, How and When?Mycopathologia · 2021Review
- A Case of Scedosporium aurantiacum Infection in the United States.Mycopathologia · 2021Article
- Phenomic profiling of a novel sibling species within the Scedosporium complex in Thailand.BMC microbiology · 2021Article
- Multilocus Sequence Typing Reveals Extensive Genetic Diversity of the Emerging Fungal PathogenFrontiers in cellular and infection microbiology · 2021Article
- Characterization of antimicrobial effect of organotin-based catalysts on diesel-biodiesel deteriogenic microorganisms.Environmental monitoring and assessment · 2020Article
- First reported case of disseminatedIDCases · 2020Article
- Misidentification ofCase reports in infectious diseases · 2020Article
- Canine rhinitis caused by an uncommonly-diagnosed fungus, Scedosporium apiospermum.Medical mycology case reports · 2018Article
- Review
- Varying susceptibility of clinical and environmental Scedosporium isolates to chemical oxidative stress in conidial germination.Archives of microbiology · 2018Article
- Fungal Olecranon Bursitis in an Immunocompetent Patient by Knoxdaviesia dimorphospora sp. nov.: Case Report and Review.Mycopathologia · 2018Review
- Ecology of Scedosporium Species: Present Knowledge and Future Research.Mycopathologia · 2018Review
- Fungus-Specific CD4 T Cells as Specific Sensors for Identification of Pulmonary Fungal Infections.Mycopathologia · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eighty-four isolates belonging to eight species that constitute the Pseudallescheria boydii complex were tested against 11 antifungal agents by using the microdilution method. There were significant differences among the species, with Scedosporium aurantiacum being the most resistant. In general, voriconazole was the most active drug, followed by posaconazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.